Evidence map›Paper›PMID 27068494›Full record

ArticleTissue engineering. Part A2016

Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer.

Jeanette Bierwolf, Tassilo Volz, Marc Lütgehetmann, Lena Allweiss, Kristoffer Riecken, Michael Warlich, Boris Fehse, Joerg C Kalff, Maura Dandri, Joerg-Matthias Pollok

Open access · hybridAbstract read
In one paragraph

Article in Tissue engineering. Part A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Mice Engrafted with Human Liver Cells.Seminars in liver disease · 2024
    Review
  4. Review
  5. Article
  6. Novel vectors and approaches for gene therapy in liver diseases.JHEP reports : innovation in hepatology · 2021
    Review
  7. Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jeanette Bierwolf1 Department for General, Visceral, Thoracic, and Vascular Surgery, University Medical Center Bonn , Bonn, Germany .
Tassilo Volz2 Department of Internal Medicine, University Medical Center Hamburg-Eppendorf , Hamburg, Germany .
Marc Lütgehetmann2 Department of Internal Medicine, University Medical Center Hamburg-Eppendorf , Hamburg, Germany .
Lena Allweiss2 Department of Internal Medicine, University Medical Center Hamburg-Eppendorf , Hamburg, Germany .
Kristoffer Riecken4 Department of Stem Cell Transplantation, Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf , Hamburg, Germany .
Michael Warlich2 Department of Internal Medicine, University Medical Center Hamburg-Eppendorf , Hamburg, Germany .
Boris Fehse4 Department of Stem Cell Transplantation, Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf , Hamburg, Germany .
Joerg C Kalff1 Department for General, Visceral, Thoracic, and Vascular Surgery, University Medical Center Bonn , Bonn, Germany .
Maura Dandri2 Department of Internal Medicine, University Medical Center Hamburg-Eppendorf , Hamburg, Germany .
Joerg-Matthias Pollok1 Department for General, Visceral, Thoracic, and Vascular Surgery, University Medical Center Bonn , Bonn, Germany .
Universität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-based therapies represent a promising alternative to orthotopic liver transplantation. However, therapeutic effects are limited by low cell engraftment rates. We recently introduced a technique creating human hepatocyte spheroids for potential therapeutic application. The aim of this study was to evaluate whether these spheroids are suitable for engraftment in diseased liver tissues. Intrasplenic spheroid transplantation into immunodeficient uPA/SCID/beige mice was performed. Hepatocyte transduction ability prior to transplantation was tested by lentiviral labeling using red-green-blue (RGB) marking. Eight weeks after transplantation, animals were sacrificed and livers were analyzed by immunohistochemistry and immunofluorescence. To investigate human hepatocyte-specific gene expression profiles in mice, quantitative real-time-PCR was applied. Human albumin and alpha-1-antitrypsin concentrations in mouse serum were quantified to assess the levels of human chimerism. Precultured human hepatocytes reestablished their physiological liver tissue architecture and function upon transplantation in mice. Positive immunohistochemical labeling of the proliferating cell nuclear antigen revealed that human hepatocytes retained their in vivo proliferation capacity. Expression profiles of human genes analyzed in chimeric mouse livers resembled levels determined in native human tissue. Extensive vascularization of human cell clusters was detected by demonstration of von Willebrand factor activity. To model gene therapy approaches, lentiviral transduction was performed ex vivo and fluorescent microscopic imaging revealed maintenance of RGB marking in vivo. Altogether, this is the first report demonstrating that cultured and retroviral transduced human hepatocyte spheroids are able to engraft and maintain their regenerative potential in vivo.

Indexed as

HepatocytesLentivirusTransduction, GeneticAnimalsGreen Fluorescent ProteinsHeterograftsHumansLiverMiceMice, SCIDMice, TransgenicTransplantation ChimeraGreen Fluorescent Proteins

Identifiers

PMID27068494
PMCPMC4876526
OpenAlexW2339409295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.